The Spanish Competition Authority clears a dual pricing system (Pfizer / Cofares)

On 19 January 2017 the Spanish Competition Authority (SCA) issued a decision clearing PFIZER of antitrust charges and blessing PFIZER’s dual pricing system (SCA Decision). In 2009, the SCA decided (First Decision) to close the antitrust investigation against COMPAÑÍA FARMACÉUTICA ESPAÑOLA, S.A. (COFARES), a wholesale distributor, and PFIZER. The investigation started following a complaint filed by SPAIN PHARMA, S.A. (SPAIN PHARMA) reporting the existence of an agreement by means of which PFIZER prevented COFARES from exporting PFIZER’s pharmaceutical specialties to other EU States and established a dual-pricing system on the basis of geographic destination of the pharmaceuticals. The First Decision was challenged by SPAIN PHARMA before the Appeal Court (AC). The AC partially upheld the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Callol, Coca & Asociados (Madrid)

Quotation

Pedro Callol, The Spanish Competition Authority clears a dual pricing system (Pfizer / Cofares), 19 January 2017, e-Competitions Bulletin January 2017, Art. N° 83837

Visites 271

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues